Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer

Published:2017-09-14 Issue:18 Volume:23 Page:5394-5405
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Feng Yan,Wang Xiaoning,Bajaj Gaurav,Agrawal Shruti,Bello Akintunde,Lestini Brian,Finckenstein Friedrich Graf,Park Jong-Soon,Roy Amit

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study);JCO Global Oncology;2024-08

2. Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer;Cancer Chemotherapy and Pharmacology;2024-07-26

3. Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer;CPT: Pharmacometrics & Systems Pharmacology;2024-05-06

4. Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?;Translational Lung Cancer Research;2024-04

5. Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy;Cancer Chemotherapy and Pharmacology;2024-03-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP